PMID-41126551 — Sa: Psychiatric Effects of GLP-1 Receptor Agonists (Systematic Review)

[DRAFT — authored 2026-04-19. Citation web-verified 2026-04-19 against PubMed. Requires Medical Director content review.]

Citation

Sa B, Maristany A, Subramaniam A, et al. Psychiatric effects of GLP-1 receptor agonists: A systematic review of emerging evidence. Diabetes, Obesity and Metabolism. 2026;28(1):50-59. doi: 10.1111/dom.70198. PMID: 41126551. PMCID: PMC12673456.

External URL: DOI resolver

Phase 1 manifest note: This paper was listed in the manifest as "psychiatric effects systematic review 2024" with identifier PMC12673456. Web-verification 2026-04-19 confirms the PMCID maps to PMID: 41126551, published January 2026 (not 2024 as the manifest date suggested). Content scope matches manifest framing.

Study Design

Design: Systematic review (PRISMA-aligned) of peer-reviewed evidence on psychiatric effects of GLP-1 receptor agonists
Scope: Depression, suicidality, eating disorders, substance use disorders, schizophrenia spectrum disorders
Evidence sources: RCTs, observational studies, pharmacovigilance analyses, mechanistic/CNS-penetration research

Key Findings

Antidepressant effects: Modest signal for improvement in depressive symptoms with GLP-1 RA therapy; effect size small and heterogeneous across studies
Suicidality: Associations inconsistent across data sources; no clear causal signal when pharmacovigilance, cohort, and RCT evidence are integrated
Eating disorders: Emerging data suggests therapeutic potential in binge eating disorder and related reward-dysregulation conditions; mechanism plausible given GLP-1 effects on mesolimbic reward circuits
Substance use disorders: Small-but-growing evidence base for GLP-1 RA effects on alcohol and nicotine consumption — potentially therapeutic, pending RCT confirmation
Schizophrenia spectrum: GLP-1 therapies offer metabolic benefits (weight gain, glycemic impact from antipsychotics); psychiatric symptom effects not consistently established
Methodological caveats: Underrepresentation of patients with psychiatric conditions in pivotal obesity/T2D RCTs; heterogeneity in outcome measures; limited sample diversity

Clinical Relevance

Sa 2026 provides the most current peer-reviewed synthesis of the psychiatric-safety-and-effect landscape for GLP-1 RAs. Alongside the suicidal-ideation meta-analysis (PMID-39945396 – Suicidal Ideation GLP1 Meta-Analysis) and the FDA's January 2024 safety communication (REG-FDA-Suicidal-Ideation-Review-2024 – FDA GLP1 Suicidal Ideation Null Finding), it supports a triangulated framing for clinician counseling:

Mental-health screening is reasonable, not mandatory per label — routine intake questionnaires (PHQ-9, GAD-7, history screen) are appropriate given the patient-population overlap between obesity care and mood-disorder burden
No established causal signal for suicidality across the aggregated evidence
Potentially therapeutic directions in binge eating, substance use disorders, mood disorders — but not yet indication-qualified
Continue monitoring — heterogeneity of published evidence means the signal could evolve

Limitations (Author-acknowledged)

Systematic review includes heterogeneous study designs; narrative synthesis needed where meta-analysis not feasible
Underrepresentation of psychiatric populations in primary obesity/T2D trials biases the evidence base
Outcome measures vary across included studies
Long-term (>2 year) psychiatric-outcome data sparse

Evidence Level

Level I (Oxford CEBM for systematic reviews) — systematic review; underlying evidence tiers vary.

Linked Peptides

Related Studies

PMID-39945396 – Suicidal Ideation GLP1 Meta-Analysis (quantitative suicidality meta-analysis companion)
REG-FDA-Suicidal-Ideation-Review-2024 – FDA GLP1 Suicidal Ideation Null Finding (regulatory triangulation)

Orchestrator Notes

Manifest identifier: PMC12673456 → verified PMID: 41126551 via PubMed search.
Publication date: January 2026 (manifest had listed 2024 — corrected).
Primary reference for Lesson 5.2 mental health screening narrative (triangulated with suicidal-ideation meta and FDA null finding).

PMID-41126551 – Psychiatric Effects GLP1 Systematic Review